Specificity of 89 Zr-trastuzumab for HER2-positive tumors sorted by
relevance

Admin10.09.2021

Specificity of 89 Zr-trastuzumab for HER2-positive tumors

5403
Admin06.10.2021

Specificity of 89 Zr-trastuzumab for HER2-positive tumors

5600
Admin02.09.2021

Site-specific 89 Zr-DFO-trastuzumab PET/CT imaging in PDX

Admin22.08.2021

Specificity of 89Zr-trastuzumab for HER2-positive tumors

3402
Admin29.07.2021

Site-specific 89 Zr-DFO-trastuzumab PET/CT imaging in PDX

2202
Admin31.08.2021

[ 89 Zr]trastuzumab PET scan of a patient with HER2

Admin17.07.2021

Specificity of 89Zr-trastuzumab for HER2-positive tumors

8400
Admin26.07.2021

89 Zr-trastuzumab-PET showing uptake in a brain metastasis

78010
Admin10.08.2021

Monitoring Afatinib Treatment in HER2-Positive Gastric

35010
Admin24.09.2021

Radiochemistry and in vitro evaluation of 89 Zr-DFO

9204
Admin05.08.2021

Site-specific 89 Zr-DFO-trastuzumab PET/CT imaging in PDX

7404
Admin25.09.2021

(PDF) N-Acetylcysteine breaks resistance to trastuzumab

3709
Admin27.08.2021

Role of HER2 in Gastric Cancers | Abdominal Key

3307
Admin28.07.2021

Specificity of 89Zr-trastuzumab for HER2-positive tumors

7300
Admin21.07.2021

Detection of HER2-Positive Metastases in Patients with

5008
Admin03.10.2021

(PDF) Monitoring afatinib treatment in HER2-positive

708
Admin30.08.2021

Monitoring Afatinib Treatment in HER2-Positive Gastric

908
Admin16.08.2021

Correlative analysis between 89 Zr-trastuzumab and 18 F

1109
Admin21.07.2021

Detection of HER2-Positive Metastases in Patients with

8309
Admin07.09.2021

Zirconium-89 Labeled Antibodies: A New Tool for Molecular

87010
Admin25.08.2021

(PDF) Monitoring afatinib treatment in HER2-positive

6708